CLNN vs. GBIO, TNXP, ME, ZVRA, RANI, TSVT, XBIT, CDT, ABEO, and TRVI
Should you be buying Clene stock or one of its competitors? The main competitors of Clene include Generation Bio (GBIO), Tonix Pharmaceuticals (TNXP), 23andMe (ME), Zevra Therapeutics (ZVRA), Rani Therapeutics (RANI), 2seventy bio (TSVT), XBiotech (XBIT), Conduit Pharmaceuticals (CDT), Abeona Therapeutics (ABEO), and Trevi Therapeutics (TRVI). These companies are all part of the "pharmaceutical preparations" industry.
Generation Bio (NASDAQ:GBIO) and Clene (NASDAQ:CLNN) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their media sentiment, community ranking, valuation, profitability, dividends, analyst recommendations, earnings, institutional ownership and risk.
Clene received 22 more outperform votes than Generation Bio when rated by MarketBeat users. Likewise, 75.95% of users gave Clene an outperform vote while only 67.86% of users gave Generation Bio an outperform vote.
In the previous week, Generation Bio and Generation Bio both had 4 articles in the media. Clene's average media sentiment score of 0.73 beat Generation Bio's score of 0.70 indicating that Generation Bio is being referred to more favorably in the media.
Generation Bio has a net margin of -1,696.87% compared to Generation Bio's net margin of -7,873.23%. Clene's return on equity of -82.33% beat Generation Bio's return on equity.
95.2% of Generation Bio shares are held by institutional investors. Comparatively, 23.3% of Clene shares are held by institutional investors. 21.1% of Generation Bio shares are held by company insiders. Comparatively, 25.1% of Clene shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
Clene has lower revenue, but higher earnings than Generation Bio. Generation Bio is trading at a lower price-to-earnings ratio than Clene, indicating that it is currently the more affordable of the two stocks.
Generation Bio has a beta of 2.87, indicating that its stock price is 187% more volatile than the S&P 500. Comparatively, Clene has a beta of 0.45, indicating that its stock price is 55% less volatile than the S&P 500.
Generation Bio currently has a consensus target price of $8.00, suggesting a potential upside of 173.97%. Clene has a consensus target price of $6.50, suggesting a potential upside of 1,639.83%. Given Generation Bio's stronger consensus rating and higher probable upside, analysts clearly believe Clene is more favorable than Generation Bio.
Summary
Clene beats Generation Bio on 10 of the 17 factors compared between the two stocks.
Get Clene News Delivered to You Automatically
Sign up to receive the latest news and ratings for CLNN and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding CLNN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
